selfworthmatters hashtag performance

Silent Treatment vs. No Contact: What’s the Difference? Alright, let’s talk about something that confuses a lot of people after a breakup—the difference between the silent treatment and no contact. They might look similar on the surface, but trust me, they are NOT the same thing. One is toxic, and the other is a healthy boundary. Let’s break it down. Silent Treatment: A Form of Emotional Punishment The silent treatment is when someone deliberately ignores another person to punish, manipulate, or control them. It’s not about healing; it’s about power. This kind of behavior has been studied extensively in psychology. According to research by Williams & Nida (2011), the silent treatment activates the same brain regions associated with physical pain. In other words, when someone gives you the silent treatment, your brain processes it as if you’re being physically hurt. It creates feelings of rejection, anxiety, and emotional distress. In relationships, the silent treatment is often used as a way to make the other person feel guilty or desperate for attention. It’s emotionally abusive because it leaves the other person in a state of uncertainty, making them question what they did wrong—even if they did nothing at all. Key takeaway: Silent treatment is about control. It’s emotionally harmful, and it’s meant to make the other person suffer. No Contact: A Path to Healing Now, let’s talk about no contact. No contact isn’t about punishing anyone—it’s about protecting your own peace. After a breakup, emotions are all over the place, and staying in touch with an ex often makes it harder to heal. That’s where no contact comes in. No contact means cutting off communication so you can process your emotions, rebuild your self-esteem, and move forward. Research by Fisher et al. (2010) found that romantic rejection activates the same areas of the brain as addiction withdrawal. That’s why staying in touch with an ex can feel like an addiction—it keeps you emotionally hooked and makes it harder to detach. Going no contact helps break that cycle. Unlike the silent treatment, which is manipulative, no contact is a boundary. It’s a way of saying, “I need space to heal, and I deserve peace.” It’s not about making your ex miss you or punishing them—it’s about prioritizing yourself. Key takeaway: No contact is for YOU. It’s not about hurting anyone—it’s about healing yourself and moving forward. Final Thoughts So, if you’re wondering whether someone is giving you the silent treatment or if they’ve gone no contact, ask yourself: Is this about control, or is this about healing? • Silent treatment = punishment, manipulation, and emotional harm. • No contact = self-care, boundaries, and healing. At the end of the day, you deserve peace. And if walking away helps you find it, then that’s the healthiest choice you can make. #BreakupHealing #NoContactRule #ToxicVsHealthy #EmotionalAbuseAwareness #SelfWorthMatters

#fyp #selfworth #selfworthadvice #selfworthiseverything #selfworthmatters #selflove #humble #SelfCare #manipulative #manipulation #HealingJourney #selfimage #selfesteem #blackwomen #blackgirlmagic #blacklifecoach #lifecoach

“Winfrey, now close to her goal weight of 160 pounds, opened up on her podcast about using the medication and the insights it has given her on "thin people" while discussing the drug's function and safety with Dr. Ania Jastreboff.” “She confessed: "'One of the things that I realized the very first time I took a GLP-1 was that all these years I thought that thin people had more willpower.” "They ate better foods. They were able to stick to it longer. They never had a potato chip." “After starting a GLP-1 medication, Winfrey realized what she had considered "willpower" was actually the lack of constant hunger, or "food noise." #SelfCareTips #mentalhealthmatters #SelfCareJourney #zepboundjourney #GLP1Journey #cardiovascularhealth #WomenSupportingWomen #SelfWorthMatters #fyyyyyyyyyyyyyyyy #ozempic #ResearchBasedWellness #glp1community #ObesityIsADisease #selfcareishealthcare #fyp

#fyp #selfworth #selfworthadvice #selfworthiseverything #selfworthmatters #selflove #SelfCare #selflovejourney #selfloveclub #healing #HealingJourney #healingprocess #healingtok #selfesteem #highselfesteem #highvalue #softlife #thatgirl

“Fifty-seven percent of respondents predicted that regenerative medicine, including treatments such as platelet-rich plasma and exosome-based therapies, will become a major area of innovation in the aesthetic field. In addition, men are increasingly seeking cosmetic procedures, with 92 percent of survey respondents reporting male patients in their practice; blepharoplasty, rhinoplasty, and facelifts were the most requested procedures.” "Just like their female counterparts, neurotoxins, fillers, and skin treatments remain the top three nonsurgical procedures among men," Patrick Byrne, M.D., president of the AAFPRS, said in a statement. "This trend highlights the growing acceptance of aesthetic treatments among men and their changing approach to self-care." #selfcareishealthcare #mentalhealthmatters #SelfCareJourney #GLP1Journey #glp1community #fy #ObesityIsADisease #ResearchBasedWellness #WomenSupportingWomen #SelfWorthMatters #fypシ #SelfCareTips #cardiovascularhealth #zepboundjourney #fyyyyyyyyyyyyyyyy

“To determine whether BCL6 was involved in muscle maintenance, the team compared mice with and without functional BCL6 proteins. Mice lacking BCL6 had 40% less muscle mass than their healthy counterparts, and the muscle they did have was compromised both in structure and function. However, when the researchers increased the expression of BCL6 in the animals' muscles, this successfully reversed the losses in muscle mass and strength. And when they compared normal mice and those that had fasted overnight, they found fasting mice had less BCL6 in their muscles.” “Clearly, BCL6 was controlling muscle maintenance—but how?” “Through a series of subsequent experiments, the steps along the path became clear. Fasting promotes the secretion of growth hormone, which reduces BCL6 levels in muscle cells. BCL6 is a regulator of SOCS2, so less BCL6 leads to less SOCS2. At normal levels, this allows BCL6 to control how much SOCS2 is expressed, and therefore, how much IGF1 is made. In animals without BCL6, the lack of control over SOCS2 slowed IGF1 production so much that muscles became weaker and smaller.” #SelfWorthMatters #SelfCareTips #fyyyyyyyyyyyyyyyy #mentalhealthmatters #ozempic #SelfCareJourney #ResearchBasedWellness #zepboundjourney #glp1community #GLP1Journey #ObesityIsADisease #cardiovascularhealth #selfcareishealthcare #WomenSupportingWomen #fy

Replying to @moonranger88 #fyp #highvalue #highvaluewoman #highvalueman #selfworth #selfworthadvice #selfworthiseverything #selfworthmatters #healing #HealingJourney #blackwomen #innerwork #shadowwork #selfesteem

#foryoupage #fypシ #fypviral #fyf #harleydavidson #foryourpage #mercy #softail #viralvideo #viraltiktok #newbeginnings #scorpio #tatted #tattedgirls #imback #letsgo #fundays #bluecollarlife #bluecollarbabe #spoiled #crazy #goodheart #unapologetic #strong #selfworthmatters #natsfam💙 #hazeleyes #letsgo My seat 😆And I don't have to worry bout catching them pegs down when I ain't on it😉🤷‍♀️💥💯♥️ #abluecollarsgirl ♥️

#greenscreen Abstract “Background and aims: Weight recidivism following sleeve gastrectomy (SG) is common. Adjuvant treatments include new glucagon-like peptide 1 and glucose-dependent insulinotropic peptide receptor agonists (GLP1/GIP-RA) or revisional endoscopic sleeve gastroplasty (R-ESG). We here compare the outcomes of these treatments.” “Methods: A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre. Primary outcomes were total body weight loss (TBWL) and adverse events (AEs). Secondary outcomes were changes in metabolic parameters. Tertiary outcome was to compare GLP1/GIP-RA outcomes in SG patients to matched patients with intact stomach.” “Results: Our study included 68 (prior SG + GLP1/GIP-RA) and 22 (prior SG + R-ESG). R-ESG offered higher TBWL% than GLP1/GIP-RA at 3 (11.2% vs. 4.3%, p < .001), 6 (13.5% vs. 6.8%, p < .001) and 12 months (13.4% vs. 9.2%, p = .07) with no significant difference in AEs or change in metabolic parameters. On subgroup analysis, tirzepatide achieved similar 12-months TBWL% as R-ESG (13.2% vs. 13.4%, p = .9) and significantly more than semaglutide (13.2% vs. 8.1%, p = .04). Compared to patients with intact stomach (n = 87), GLP1/GIP-RA achieved significantly lower TBWL% in patients with prior SG at 3 (4.3% vs. 5.7%, p = .02), 6 (6.8% vs. 9.2%, p = .02) and 12 months (9.2% vs. 12.7%, p = .03). Medication refills were difficult in 41.3% of patients.” “Conclusions: In a single-centre real-world experience study, R-ESG and tirzepatide appear to offer more weight loss than semaglutide in SG patients with weight recidivism although GLP1/GIP-RA were underdosed. GLP1/GIP-RA achieved higher weight loss in patients with intact stomach than those with prior SG.” #fypシ #GLP1Journey #SelfWorthMatters #fyyyyyyyyyyyyyyyy #fyp #glp1community #ObesityIsADisease #selfcareishealthcare #SelfCareJourney #SelfCareTips #cardiovascularhealth #WomenSupportingWomen #ResearchBasedWellness #mentalhealthmatters #zepboundjourney

“GLP1RA have improved the treatment of Type 2 diabetes and could revolutionize the treatment of obesity, the researchers point out.” “GLP1RAs mimic the action of the hormone GLP-1 that binds to GLP1R in the brain and pancreas, helping to control insulin and blood glucose levels and decreasing appetite by promoting feelings of fullness.” Strawbridge and co-workers examined the impact of common genetic variants in the GLP1R gene among 408,774 White-British, 50,314 White-European, 7667 South-Asian, and 7641 African-Caribbean individuals as well as 10,437 of mixed ancestry.” “Genetic variants in GLP1R were linked with the CMts of body mass index, blood pressure and Type 2 diabetes among individuals of all ancestries.” “All participants except those of South-Asian descent also had significant associations between GLP1R variants and mental health but the results were less consistent, with various links to decreased mood instability (odds ratio [OR]=0.85), increased risk-taking behavior (OR=1.05), and decreased chronic pain (OR=0.65).” #SelfCareTips #WomenSupportingWomen #selfcareishealthcare #fyyyyyyyyyyyyyyyy #GLP1Journey #ObesityIsADisease #ResearchBasedWellness #zepboundjourney #cardiovascularhealth #ozempic #SelfWorthMatters #SelfCareJourney #mentalhealthmatters #fy #fyp

🔥 No more chasing. No more proving. No more hustling for love. #stopchasing #knowyourworth #nomorestruggle #Love #SelfLoveFirst #selflove #breakup #club #DatingTruths #RelationshipAdvice #LoveWithoutTheHustle #AttractNotChase #HighValueMindset #EmotionalIntelligence #SelfWorthMatters #ToxicLoveAwareness #LoveShouldBeEasy #DatingRealTalk #CapCut

Not my usual content but what in the heck is this? #selfcareishealthcare #WomenSupportingWomen #mentalhealthmatters #SelfWorthMatters #SelfCareJourney #fypシ

Diabetic Retinopathy Considerations “While some research suggests potential benefits of GLP-1R agonists for diabetic retinopathy, other studies indicate a possible link to its worsening or new onset. A meta-analysis of randomized clinical trials published in Survey of Ophthalmology in 2023 examined the relationship between GLP-1 receptor agonists and diabetic retinopathy. The analysis aimed to assess the impact of these medications on the progression or development of this eye condition. The findings of this meta-analysis provide insights into the complex relationship between GLP-1R agonists and diabetic retinopathy. Further research is needed to fully understand the effects of GLP-1R agonists on diabetic retinopathy and to determine the appropriate clinical management for patients with both conditions.” #glp1journey #zepboundjourney #mentalhealthmatters #ObesityIsADisease #SelfCareJourney #SelfWorthMatters #SelfCareTips #cardiovascularhealth #selfcareishealthcare #glp1community #ResearchBasedWellness #WomenSupportingWomen #fypシ #thisis54 #fyyyyyyyyyyyyyyyy #fy

“Another category that became less popular? Food away from home, spending 4% less on breakfast and 6% on dinner. The least affected? Nutrient-dense options, like yogurt and fresh produce.” “One unclear category is alcohol. "Our main estimate for alcohol purchases shows a decrease of 1.4% when analyzing all households. However, this estimate has wide confidence intervals from -5% to 2.4%. As a result, we cannot definitively conclude that alcohol purchases decline," Sylvia Hristakeva, assistant professor of marketing at Cornell University, told Just Drinks.” #SelfCareJourney #fyp #zepboundjourney #GLP1Journey #mentalhealthmatters #ObesityIsADisease #cardiovascularhealth #SelfWorthMatters #WomenSupportingWomen #SelfCareTips #selfcareishealthcare #glp1community #ResearchBasedWellness #fyyyyyyyyyyyyyyyy #fy

Always UNAPOLOGETIC!! Always like new things, thats me, not a front!!! #fy #foryoupage #justforfun #viral #viralvideo #tiktok #tiktoker #tiktoklatino #latina #mujeres #mujeresemprendedoras #unapologeticallyme #selflove #selfworthmatters #selflovejourney #selfempowerment

#greenscreen “The objective of this study is to quantitatively compare the weight loss effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in adult patients with no diabetes and type 2 diabetes (T2D). PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase have been used as data sources from database inception to January 6, 2024. A total of 137 trials, encompassing 310 treatment arms, 17 GLP-1RAs, and 56,683 patients, were included in the analysis. The included trials were divided into three groups based on the characteristics of the populations: nondiabetic overweight or obesity group (NDOOG), type 2 diabetes Caucasian group (T2DCG), and type 2 diabetes Asian group (T2DAG). The effects of covariates were further evaluated, patients with a higher baseline body weight tend to have better weight loss outcomes, and patients with a higher baseline glycated hemoglobin (HbA1c) tend to achieve better blood sugar control. Five mathematical models were subjected to longitudinal analysis. In terms of Δ body weight, retatrutide (12 mg qw) was the most effective treatment (mean difference = -26.56% [95% confidence interval: -43.89% to -3.01%]). Tirzepatide (15 mg qw) demonstrated good weight loss ability in all three ΔBW models, ΔBW-NDOOG (-22.76% [-26.45% to -18.50%]), ΔBW-T2DCG (-11.09% [-12.39% to -9.44%])), and ΔBW-T2DAG (-4.97% [-5.84% to -4.12%]). In the aspect of ΔHbA1c, tirzepatide (10 mg qw) and oral orforglipron (10 mg qd) were the most effective drug, respectively. GLP-1RAs demonstrated effective weight management in both nondiabetic and T2D populations. Retatrutide achieved the most pronounced weight reduction, followed by tirzepatide. GLP-1RAs also significantly improved glycemic control for patients with T2D, with tirzepatide performing the best for glycemic control.” #GLP1Journey #fyyyyyyyyyyyyyyyy #glp1community #selfcareishealthcare #SelfCareTips #WomenSupportingWomen #mentalhealthmatters #fy #SelfWorthMatters #fyp #ObesityIsADisease #SelfCareJourney #cardiovascularhealth #ResearchBasedWellness #zepboundjourney

“Successful treatment of obesity requires a multidisciplinary approach including dietary strategy, physical activity, and behavioral modification. The seven FDA-approved anti-obesity medications are phentermine, orlistat, phentermine/topiramate ER, naltrexone SR/bupropion SR, liraglutide 3.0 mg, semaglutide 2.4 mg, and tirzepatide. Obesity is a chronic disease and these medications should be prescribed with the intention of long-term use. In this article, we summarize data from phase 3 clinical trials which led to drug approval, and we review the clinical indications, mechanism of action, dosing/administration, side effects, drug interactions and contraindications for each medication.” #SelfCareJourney #ObesityIsADisease #fypシ #mentalhealthmatters #fy #SelfWorthMatters #zepboundjourney #selfcareishealthcare #glp1community #WomenSupportingWomen #cardiovascularhealth #GLP1Journey #ResearchBasedWellness #SelfCareTips #fyyyyyyyyyyyyyyyy

Abstract “Background: Obesity is a growing global epidemic, with glucagon-like peptide-1 (GLP-1) receptor agonists emerging as effective pharmacological solutions for weight loss. However, these medications raise concerns in the context of aesthetic and reconstructive surgery due to their effects on wound healing, adipose tissue metabolism, and their potential impact on surgical outcomes.” “Objective: To report two cases of delayed wound healing and fat necrosis in patients undergoing breast surgery while receiving GLP-1 receptor agonists for weight management.” “Materials and methods: In our private clinical practice, two patients were observed. Both underwent breast surgeries (implant exchange with mastopexy and reduction mammoplasty) while using GLP-1 agonists (liraglutide). One patient continued therapy perioperatively, while the other discontinued seven days prior to surgery.” “Results: Both patients experienced delayed wound healing. Wound dehiscence followed a characteristic progression involving fat necrosis and secondary healing. Despite standard surgical techniques and postoperative care, healing was prolonged in both cases.” “Discussion: These findings highlight the potential impact of GLP-1-induced rapid weight loss on surgical outcomes. Current guidelines recommend therapy suspension to avoid anesthetic complications, but further studies are needed to evaluate the necessity of preoperative discontinuation in terms of surgical outcomes.” #SelfCareTips #SelfCareJourney #WomenSupportingWomen #GLP1Journey #fyyyyyyyyyyyyyyyy #mentalhealthmatters #ObesityIsADisease #ResearchBasedWellness #zepboundjourney #cardiovascularhealth #SelfWorthMatters #ozempic #glp1community #selfcareishealthcare #fyp

“This large-scale cohort study provides compelling support for the potential role of GLP-1RAs as a cancer-risk reduction agent in individuals with obesity. Our findings reveal a complex interplay between these drugs and cancer risk that extends beyond their established metabolic effects. Importantly, there was a consistent decrease in cancer risk across multiple organ systems over the five-year follow-up period. Collectively, our results demonstrated significant risk reductions encompassing 25 different cancer types, including digestive tract, skin (including melanoma), breast, and female genital organs, especially uterine cancer. Our study design provides unique methodological strengths through propensity score matching that balanced baseline BMI, diabetes status, and other relevant covariates between GLP-1RA users and controls. This matching approach helps isolate the effect of GLP-1RA treatment from confounding metabolic factors, suggesting potential protective effects independent of baseline weight status.” #SelfCareTips #SelfCareJourney #GLP1Journey #fyyyyyyyyyyyyyyyy #WomenSupportingWomen #mentalhealthmatters #ResearchBasedWellness #ObesityIsADisease #cardiovascularhealth #zepboundjourney #ozempic #SelfWorthMatters #selfcareishealthcare #glp1community #fy

I can’t make this up LMAOOOO #tired #selfworthmatters #drained #single

“Two Major Barriers: Cost and Coverage Although shortages have prevented some from getting access to semaglutide and tirzepatide, the shortages of both are over for the time being.” “Currently, cost is perhaps the biggest barrier to access for most people. GLP-1 RAs are known to be expensive. Insurance coverage and manufacturer coupons can make GLP-1 RAs much more affordable with significant discounts to the list price. However, there’s a wide variation when it comes to insurance coverage of GLP-1 RAs for obesity treatment or weight loss.” “Medicare doesn’t cover the cost of these medications solely for weight loss, although Medicare Part D will cover the cost of Wegovy for patients if the patients have an additional medically accepted indication, such as a history of cardiovascular disease. Many state Medicaid programs don’t cover the cost for weight loss purposes either. Some private insurance companies cover part of the cost for this purpose, but many don’t. A May 2024 Kaiser Family Foundation Health Tracking Poll found that even among the majority of patients with insurance, the cost of GLP-1 RAs was “ difficult to afford.” #SelfCareTips #SelfCareJourney #GLP1Journey #WomenSupportingWomen #fyyyyyyyyyyyyyyyy #ResearchBasedWellness #ObesityIsADisease #mentalhealthmatters #zepboundjourney #cardiovascularhealth #SelfWorthMatters #ozempic #glp1community #selfcareishealthcare #fy